GYRE has been in the news 313% more than usual
Jan 08, 2026, 9:33 PM
4.09%
What does GYRE do
Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: Evogene Ltd. has partnered with Unravel Biosciences to develop a small-molecule therapy aimed at myelin restoration for approximately 3 million multiple sclerosis patients globally. Additionally, Harmony Biosciences Holdings received mixed analyses from six analysts, reflecting varied opinions on its market performance.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.